Arkolith/Insider Trading/CYCC/Form 4

Lazar David E.

Interim CEO, 10% OwnerCyclacel Pharmaceuticals, Inc. (CYCC) · full profile →Form 4 · filed Feb 28, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$5.8M
Net Open-Market Flow
-$5.8M
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 26, 2025Sell(S)194.6M$0.03$5.8M0
Feb 26, 2025Option exercise(M)2.6M——2.6M
Feb 26, 2025Option exercise(M)192.0M——194.6M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 26, 2025Option exercise(M)1.0M——0
Feb 26, 2025Option exercise(M)1.7M——355K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000921895-25-000651) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML